当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析 - 现金流量表

上海医药

(601607)

  

流通市值:468.87亿  总市值:623.38亿
流通股本:27.89亿   总股本:37.08亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金232,298,109,649.07154,053,366,202.374,380,745,244.37310,476,389,933.39
  收到的税费返还164,118,446.12109,855,354.6451,627,668.16215,861,045.48
  收到其他与经营活动有关的现金3,104,565,758.32,556,708,318.271,206,887,070.233,071,842,865.88
  经营活动现金流入小计235,566,793,853.49156,719,929,875.2175,639,259,982.76313,764,093,844.75
  购买商品、接受劳务支付的现金202,703,350,219.85135,698,209,949.9466,948,554,202.12277,210,199,143.72
  支付给职工以及为职工支付的现金7,735,582,192.445,831,131,741.992,849,976,624.7811,384,470,428.2
  支付的各项税费6,589,972,182.194,363,036,457.172,246,061,589.517,699,771,165.26
  支付其他与经营活动有关的现金13,191,068,151.046,378,042,478.014,604,361,940.4811,315,451,728.2
  经营活动现金流出小计230,219,972,745.52152,270,420,627.1176,648,954,356.89307,609,892,465.38
  经营活动产生的现金流量净额5,346,821,107.974,449,509,248.1-1,009,694,374.136,154,201,379.37
二、投资活动产生的现金流量:
  收回投资收到的现金41,950,103,578.9625,040,393,817.516,602,451,639.0664,905,208,473.37
  取得投资收益收到的现金338,997,271.21113,641,41614,243,328.17533,339,309.47
  处置固定资产、无形资产和其他长期资产收回的现金净额165,981,822.43171,004,797.66106,338,795.63105,146,870.85
  处置子公司及其他营业单位收到的现金净额195,055,668.332,617,197.942,617,197.9440,221,651.24
  收到的其他与投资活动有关的现金1,543,854,637.591,342,676,726.4960,000,0001,435,611,552.97
  投资活动现金流入小计44,193,992,978.5226,670,333,955.66,785,650,960.867,019,527,857.9
  购建固定资产、无形资产和其他长期资产支付的现金1,549,656,575.511,040,988,005.6687,114,232.512,325,878,841.63
  投资支付的现金40,836,533,556.7223,805,749,556.726,315,309,056.7266,832,506,032.91
  取得子公司及其他营业单位支付的现金---280,306,149.16
  支付其他与投资活动有关的现金1,809,546,995.591,430,000,00070,000,0001,563,066,489.9
  投资活动现金流出小计44,195,737,127.8226,276,737,562.327,072,423,289.2371,001,757,513.6
  投资活动产生的现金流量净额-1,744,149.3393,596,393.28-286,772,328.43-3,982,229,655.7
三、筹资活动产生的现金流量:
  吸收投资收到的现金392,000,000392,000,000-23,928,175.7
  其中:子公司吸收少数股东投资收到的现金392,000,000392,000,000-16,550,000
  取得借款收到的现金44,368,005,278.8332,255,426,049.5420,209,326,091.7661,326,650,569.91
  发行债券收到的现金8,999,416,388.895,999,628,055.562,999,852,5007,997,083,333.33
  收到其他与筹资活动有关的现金567,299,828.2630,310,263.9382,501,000220,182,772.32
  筹资活动现金流入小计54,326,721,495.9838,677,364,369.0323,291,679,591.7669,567,844,851.26
  偿还债务支付的现金55,398,610,721.0537,835,602,901.0822,124,665,813.9470,215,579,438.45
  分配股利、利润或偿付利息支付的现金3,521,200,140.071,386,699,569.06830,241,941.483,851,752,338.09
  其中:子公司支付给少数股东的股利、利润563,055,585393,103,543.05155,045,608.191,051,801,460.89
  支付其他与筹资活动有关的现金551,107,584.63403,451,945.49184,430,354.991,152,281,453.3
  筹资活动现金流出小计59,470,918,445.7539,625,754,415.6323,139,338,110.4175,219,613,229.84
  筹资活动产生的现金流量净额-5,144,196,949.77-948,390,046.6152,341,481.35-5,651,768,378.58
四、汇率变动对现金及现金等价物的影响-4,468,383.79-8,971,209.55-8,778,258.86-3,115,599.14
五、现金及现金等价物净增加额196,411,625.113,885,744,385.23-1,152,903,480.07-3,482,912,254.05
  加:期初现金及现金等价物余额28,398,360,540.8228,398,360,540.8228,398,360,540.8231,881,272,794.87
  期末现金及现金等价物余额28,594,772,165.9332,284,104,926.0527,245,457,060.7528,398,360,540.82
补充资料:
  净利润-4,341,656,313.04-6,973,717,681.49
  资产减值准备-28,045,168.32-1,018,555,938.73
  固定资产和投资性房地产折旧-754,363,642.25-1,512,910,120.05
  无形资产摊销-324,159,569.06-602,493,205.87
  长期待摊费用摊销-84,318,125.33-198,488,749.61
  处置固定资产、无形资产和其他长期资产的损失--179,699,818.59--157,152,717.09
  公允价值变动损失--1,951,396.44--332,120,868.45
  财务费用-692,661,912.58-1,669,610,270.78
  投资损失--921,381,409.6--3,409,098,249.27
  递延所得税--185,338,212.82-572,259,675.46
  其中:递延所得税资产减少--224,320,335.41-37,097,310.92
    递延所得税负债增加-38,982,122.59-535,162,364.54
  存货的减少-2,635,897,136.23--5,196,581,328.95
  经营性应收项目的减少--6,504,749,025.29--3,668,534,969.05
  经营性应付项目的增加-2,517,684,376.96-5,048,228,397.42
  现金的期末余额-32,284,104,926.05-28,398,360,540.82
  减:现金的期初余额-28,398,360,540.82-31,881,272,794.87
  现金及现金等价物的净增加额-3,885,744,385.23--3,482,912,254.05
公告日期2026-10-302026-08-282026-04-302026-03-31
审计意见(境内)标准无保留意见
TOP↑